Research progress in the treatment of central serous chorioretinopathy
Author:
Fund Project:

Chongqing Municipal Natural Science Foundation(No.CSTB2023NSCQ-MSX0245)

  • Article
  • | |
  • Metrics
  • |
  • Reference [53]
  • |
  • Related [20]
  • | | |
  • Comments
    Abstract:

    Central serous chorioretinopathy(CSC)is a macular disease predominantly affecting young to middle-aged adults, characterized by serous retinal detachment in the posterior pole, leading to symptoms such as decreased central vision, visual distortion, and color changes. The disease has a certain degree of self-limitation but can recur. The pathogenesis is still uncertain and the treatment is controversial. Commonly used treatments include medication, retinal laser, photodynamic therapy(PDT)and vitreous anti-vascular endothelial growth factor(VEGF)therapy which have emerged in recent years, but the treatment of recurrent CSC is still tricky. The purpose of this article is to review the current therapeutic approaches regarding CSC, with a view to providing a reference for clinical treatment.

    Reference
    \〖1\〗 Singh SR,Iovino C, Zur D, et al. Central serous chorioretinopathy imaging biomarkers. Br J Ophthalmol, 2022,106(4):553-558.
    \〖2\〗 Bujarborua D. Long-term follow-up of idiopathic central serous chorioretinopathy without laser. Acta Ophthalmol Scand, 2001,79(4):417-421.
    \〖3\〗 Singh SR,Dogra M, Dogra MR. Dark spot in fibrinous central serous chorioretinopathy. JAMA Ophthalmol, 2018,136(10):e182924.
    \〖4\〗 Tewari HK, Gadia R, Kumar D, et al. Sympathetic-parasympathetic activity and reactivity in central serous chorioretinopathy: a case-control study. Invest Ophthalmol Vis Sci, 2006,47(8):3474-3478.
    \〖5\〗 Chatziralli I, Kabanarou SA, Parikakis E, et al. Risk factors for central serous chorioretinopathy: multivariate approach in a case-control study. Curr Eye Res, 2017,42(7):1069-1073.
    \〖6\〗 Liu B, Deng T, Zhang JJ. Risk factors for central serous chorioretinopathy: a systematic review and meta-analysis. Retina, 2016,36(1):9-19.
    \〖7\〗 李璐希, 张鹏, 王延辉, 等. 阻塞性睡眠呼吸暂停综合征与中心性浆液性脉络膜视网膜病变的相关性研究. 中华眼底病杂志, 2020,36(9):714-717.
    \〖8\〗 Hosoda Y, Yoshikawa M, Miyake M, et al. CFH and VIPR2 as susceptibility loci in choroidal thickness and pachychoroid disease central serous chorioretinopathy. Proc Natl Acad Sci U S A, 2018,115(24):6261-6266.
    \〖9\〗 Nicholson BP, Atchison E,Idris AA, et al. Central serous chorioretinopathy and glucocorticoids: an update on evidence for association. Surv Ophthalmol, 2018,63(1):1-8.
    \〖10\〗 Tittl MK, Spaide RF, Wong D, et al. Systemic findings associated with central serous chorioretinopathy. Am J Ophthalmol, 1999,128(1):63-68.
    \〖11\〗 Behar-Cohen F, Zhao M. Corticosteroids and the retina: a role for the mineralocorticoid receptor. Curr Opin Neurol, 2016,29(1):49-54.
    \〖12\〗 Fraenkel D, Suffo S, Langenbucher A, et al. Eplerenone for treatment of chronic central serous chorioretinopathy. Eur J Ophthalmol, 2021,31(4):1885-1891.
    \〖13\〗 Gao S, Zhang Y, Zhang MX. Efficacy and predictive factors of oral spironolactone treatment in chronic central serous chorioretinopathy. J Ophthalmol, 2024,2024:7197249.
    \〖14\〗 Yang D,Eliott D. Systemic mineralocorticoid antagonists in the treatment of central serous chorioretinopathy. Semin Ophthalmol, 2017,32(1):36-42.
    \〖15\〗 Kapoor KG, Wagner AL. Mineralocorticoid antagonists in the treatment of central serous chorioretinopathy: a comparative analysis. Ophthalmic Res, 2016,56(1):17-22.
    \〖16\〗 Caccavale A, Romanazzi F, Imparato M, et al. Low-dose aspirin as treatment for central serous chorioretinopathy. Clin Ophthalmol, 2010,4:899-903.
    \〖17\〗 Bahadorani S, MacLean K, Wannamaker K, et al. Treatment of central serous chorioretinopathy with topical NSAIDs. Clin Ophthalmol, 2019,13:1543-1548.
    \〖18\〗 薛愚愚, 周琦, 宿晓娟, 等. 幽门螺杆菌与眼部疾病相关性研究进展. 国际眼科杂志, 2023,23(7):1158-1162.
    \〖19\〗 Wuarin R, Kakkassery V, Consigli A, et al. Combined topical anti-inflammatory and oral acetazolamide in the treatment of central serous chorioretinopathy. Optom Vis Sci, 2019,96(7):500-506.
    \〖20\〗 陈莲, 何珂, 李晓清, 等. 非那雄胺在慢性中心性浆液性脉络膜视网膜病变患者中的应用. 眼科新进展, 2020,40(5):474-477.
    \〖21\〗 李铭, 魏伟. 中医对黄斑部疾病的认识. 中国中医眼科杂志, 2018,28(6):383-388.
    \〖22\〗 陈洋, 张南, 许家骏, 等. 利水祛湿法分期治疗中心性浆液性脉络膜视网膜病经验. 中华中医药杂志, 2022,37(12):7201-7204.
    \〖23\〗 刘鹏, 张必萌, 张开勇, 等. 三部配穴法针刺治疗慢性中心性浆液性脉络膜视网膜病变的临床效果. 中国医药导报, 2024,21(3):131-134.
    \〖24\〗 罗英子, 郑香悦, 俞晓艺. 关国华辨治岭南地区中心性浆液性脉络膜视网膜病变经验. 广州中医药大学学报, 2024,41(3):759-763.
    \〖25\〗 Chen J, Wang ZZ, Zhang S, et al. Does mineralocorticoid receptor play a vital role in the development of depressive disorder? Life Sci, 2016,152:76-81.
    \〖26\〗 Sakalar YB, Keklikci U, Unlu K, et al. Effects of photodynamic therapy with verteporfin for the treatment of chronic central serous chorioretinopathy: an uncontrolled, open-label, observational study. Curr Ther Res, 2010,71(3):173-185.
    \〖27\〗 Höhn F, Kretz F, Beger I, et al. Photodynamische Therapie mit halber Verteporfin-Dosis zur Behandlung der Chorioretinopathia Centralis Serosa. Klin Monatsbl Augenheilkd, 2015,233(7):860-863.
    \〖28\〗 Sheptulin V, Purtskhvanidze K, Roider J. Half-time photodynamic therapy in treatment of chronic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol, 2018,256(11):2027-2034.
    \〖29\〗 Servillo A, Sacconi R, Zucchiatti I, et al. No-dose photodynamic therapy against half-dose photodynamic therapy for treatment of central serous chorioretinopathy. Ophthalmol Ther, 2023,12(4):2199-2208.
    \〖30\〗 Schmidt-Erfurth U, Laqua H, Schlötzer-Schrehard U, et al. Histopathological changes following photodynamic therapy in human eyes. Arch Ophthalmol, 2002,120(6):835-844.
    \〖31\〗 Maltsev DS, Kulikov AN, Vasiliev AS, et al. Safety and efficacy of photodynamic therapy with chlorin e6 in chronic central serous chorioretinopathy. Retina, 2024,44(8):1387-1393.
    \〖32\〗 Shiragami C, Takasago Y, Osaka R, et al. Clinical features of central serous chorioretinopathy with type 1 choroidal neovascularization. Am J Ophthalmol, 2018,193:80-86.
    \〖33\〗 Asahi MG, Chon AT,Gallemore E, et al. Photodynamic therapy combined with antivascular endothelial growth factor treatment for recalcitrant chronic central serous chorioretinopathy. Clin Ophthalmol, 2017,11:2051-2056.
    \〖34\〗 Shiraya T, Araki F, Nakagawa S, et al. Differential gene expression analysis using RNA sequencing: retinal pigment epithelial cells after exposure to continuous-wave and subthreshold micropulse laser. Jpn J Ophthalmol, 2022,66(5):487-497.
    \〖35\〗 vanRijssen TJ, van Dijk EHC, Yzer S, et al. Central serous chorioretinopathy: Towards an evidence-based treatment guideline. Prog Retin Eye Res, 2019,73:100770.
    \〖36\〗 路雪, 谢兵. 阈值下微脉冲激光在中心性浆液性脉络膜视网膜病变中的作用机制. 国际眼科杂志, 2024,24(5):749-752.
    \〖37\〗 齐元, 刘丽娅, 马菲妍, 等. 阈值下微脉冲激光治疗中心性浆液性脉络膜视网膜病变的研究新进展. 中华眼底病杂志, 2023,39(4):337-340.
    \〖38\〗 Uzlu D, Erdöl H, Kola M, et al. The efficacy of subthreshold micropulse yellow laser(577 nm)in chronic central serous chorioretinopathy. Lasers Med Sci, 2021,36(5):981-988.
    \〖39\〗 Chhablani J, SOLS(Subthreshold Laser Ophthalmic Society)writing committee. Subthreshold laser therapy guidelines for retinal diseases. Eye(Lond), 2022,36(12):2234-2235.
    \〖40\〗 Sitnilska V, Schiller P, Krohne TU, et al. Half-dose photodynamic therapy versus 577nm subthreshold pulse laser therapy in treatment-naive patients with central serous chorioretinopathy. BMC Ophthalmol, 2024,24(1):8.
    \〖41\〗 Desmettre T, Maurage CA, Mordon S. Heat shock protein hyperexpression on chorioretinal layers after transpupillary thermotherapy. Invest Ophthalmol Vis Sci, 2001,42(12):2976-2980.
    \〖42\〗 Manayath GJ, Karandikar SS, Narendran S, et al. Low fluence photodynamic therapy versus graded subthreshold transpupillary thermotherapy for chronic central serous chorioretinopathy: results from a prospective study. Ophthalmic Surg Lasers Imaging Retina, 2017,48(4):334-338.
    \〖43\〗 Romdhane K, Zola M, Matet A, et al. Predictors of treatment response to intravitreal anti-vascular endothelial growth factor(anti-VEGF)therapy for choroidal neovascularisation secondary to chronic central serous chorioretinopathy. Br J Ophthalmol, 2020,104(7):910-916.
    \〖44\〗 Nourinia R, Ahmadieh H, Nekoei E, et al. Changes in central choroidal thickness after treatment of diabetic macular edema with intravitreal bevacizumab correlation with central macular thickness and best-corrected visual acuity. Retina, 2018,38(5):970-975.
    \〖45\〗 Shin MC, Lim JW. Concentration of cytokines in the aqueous humor of patients with central serous chorioretinopathy. Retina, 2011,31(9):1937-1943.
    \〖46\〗 郭建杰, 李秀娟. 康柏西普治疗慢性中心性浆液性脉络膜视网膜病变的效果观察. 中华眼外伤职业眼病杂志, 2022,44(8):583-587.
    \〖47\〗 Park J, Hwang SH, Nam DH, et al. Changes in aqueous concentrations of various cytokines after intravitreal bevacizumab injection for chronic central serous chorioretinopathy. Korean J Ophthalmol, 2023,37(6):453-461.
    \〖48\〗 Zhao TT, Li JN, Wang YB, et al. Intravitreal injections with anti-VEGF agent aflibercept versus subthreshold micropulse laser for chronic central serous chorioretinopathy: the alternative treatment regimens for verteporfin-shortage in China. Ann Med, 2023,55(1):2227424.
    \〖49\〗 Lim JW,Ryu SJ, Shin MC. The effect of intravitreal bevacizumab in patients with acute central serous chorioretinopathy. Korean J Ophthalmol, 2010,24(3):155-158.
    \〖50\〗 Feenstra HMA, van Dijk EHC, Cheung CMG, et al. Central serous chorioretinopathy: an evidence-based treatment guideline. Prog Retin Eye Res, 2024,101:101236.
    \〖51\〗 Yoshioka H,Katsume Y. Experimental central serous chorioretinopathy. III: ultrastructural findings. Jpn J Ophthalmol, 1982,26(4):397-409.
    \〖52\〗 Frambach DA, Fain GL, Farber DB, et al. Beta adrenergic receptors on cultured human retinal pigment epithelium. Invest Ophthalmol Vis Sci, 1990,31(9):1767-1772.
    \〖53\〗 Gonçalves AN, Messias A, Chaves L, et al. Safety of intravitreal metoprolol in eyes with central serous chorioretinopathy. Doc Ophthalmol, 2022,145(3):211-219.
    Cited by
    Comments
    Comments
    分享到微博
    Submit
Get Citation

Mo Chunyan, Wang Peng. ,/et al.Research progress in the treatment of central serous chorioretinopathy. Guoji Yanke Zazhi( Int Eye Sci) 2025;25(2):242-245

Copy
Share
Article Metrics
  • Abstract:51
  • PDF: 127
  • HTML: 0
  • Cited by: 0
Publication History
  • Received:May 06,2024
  • Revised:December 18,2024
  • Online: January 14,2025